Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
- Takeda to Sell URL Pharma’s Generic Drug Business to Caraco
December 19, 2012
- Elmed Eisai, Kobayashi Kako Allegra Generics Not Launched on December 14
December 18, 2012
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
- Takeda Launches Phone Service to Support Patients’ Drug Administration
December 17, 2012
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
- AstraZeneca’s Novel RA Drug Fostamatinib Fails to Demonstrate Non-Inferiority to Humira in PIIb Study
December 17, 2012
- Eli Lilly to Conduct Additional Trial of Novel AD Treatment Solanezumab
December 17, 2012
- Eli Lilly to Discontinue One of Three PIII Rheumatoid Arthritis Registration Studies of Tabalumab
December 17, 2012
- Janssen Research & Development Submits NDA for Canagliflozin/Metformin Fixed-Dose Combination in the US
December 17, 2012
- Eisai Concludes Strategic Manufacturing Alliance with Biogen Idec for Contract Manufacturing at Eisai Inc.’s US Plant
December 17, 2012
- Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
- Calls by MRs from Pfizer Japan Left Best Impression at Insurance Pharmacies in October: Nextit Research
December 14, 2012
- ADCETRIS Shows Tolerability in Untreated HL Patients: Takeda
December 14, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…